Initiate Biologic Therapy with a TNF Inhibitor
For a man with ankylosing spondylitis who has inadequate response to NSAIDs and normal laboratory work, the next step is to start a TNF inhibitor (such as adalimumab, etanercept, infliximab, certolizumab, or golimumab). This represents the standard of care based on high-quality evidence 1.
Treatment Algorithm
Step 1: Confirm Active Disease
- Verify the patient has active disease causing symptoms at an unacceptably bothersome level, judged by the examining clinician to be due to inflammation 1
- Normal lab work (normal CRP/ESR) does NOT exclude active disease in AS—clinical assessment takes priority
- Assess disease activity using validated measures (ASDAS or BASDAI)
Step 2: Avoid Conventional DMARDs
Do NOT use sulfasalazine, methotrexate, or leflunomide for purely axial disease 2, 1. These agents are strongly recommended against in patients with axial-only involvement and have shown no benefit over placebo for axial symptoms 2. The only exception is if prominent peripheral arthritis is present, where sulfasalazine may have modest benefit 2, 1.
Step 3: Initiate Biologic Therapy
First-line biologic: TNF inhibitor 1
- The 2019 ACR/SAA/SPARTAN guidelines provide a strong recommendation (high-quality evidence) for TNF inhibitors over no treatment in active AS despite NSAIDs 1
- TNF inhibitors are conditionally recommended over IL-17 inhibitors (secukinumab/ixekizumab) as first-line biologic therapy 1
- No particular TNF inhibitor is preferred—all five approved agents (infliximab, etanercept, adalimumab, certolizumab, golimumab) have similar efficacy 1
Alternative biologics:
- IL-17 inhibitors (secukinumab or ixekizumab) are strongly recommended over no treatment but are conditionally preferred as second-line after TNF inhibitor failure, or first-line if TNF inhibitors are contraindicated 2, 1
- JAK inhibitors (tofacitinib) should only be used when biologics are contraindicated or unavailable 2
Step 4: Adjunctive Therapy
Add physical therapy with supervised exercise programs—this has a strong recommendation with moderate-quality evidence 1. Active, land-based physical therapy interventions are preferred over passive modalities 1.
Key Clinical Considerations
Why Not Conventional DMARDs?
The 2023 PANLAR guidelines explicitly state: "treatment with sulfasalazine, methotrexate or leflunomide is strongly recommended against" for purely axial disease 2. Multiple RCTs have shown these agents provide no benefit for axial symptoms 2.
Normal Labs Don't Change Management
Normal inflammatory markers (CRP/ESR) do NOT preclude biologic therapy. Clinical assessment of active disease is what matters—approximately 40-50% of AS patients have normal inflammatory markers despite active disease.
Choice Between TNF Inhibitor vs IL-17 Inhibitor
While both are effective, TNF inhibitors are preferred first-line based on:
- Longer track record and more extensive evidence
- Better efficacy for extra-articular manifestations (uveitis, IBD) 3, 4
- The 2019 ACR guidelines conditionally recommend TNF inhibitors over IL-17 inhibitors as initial biologic 1
Consider IL-17 inhibitor first if:
- History of demyelinating disease (contraindication to TNF inhibitors)
- History of congestive heart failure
- Primary non-response to first TNF inhibitor 1
What NOT to Do
- Do not add methotrexate or sulfasalazine to the TNF inhibitor—this provides no additional benefit and is conditionally recommended against 1
- Do not use systemic glucocorticoids—strongly recommended against 1
- Do not use tofacitinib as first-line when biologics are available 2
Monitoring After Initiation
Assess response at 3-6 months using disease activity measures. If primary non-response occurs, switch to an IL-17 inhibitor (secukinumab or ixekizumab) 1. If secondary non-response occurs after initial improvement, switch to another TNF inhibitor with the same or different mechanism 2, 1.